Logo image of MURA

MURAL ONCOLOGY PLC (MURA) Stock Fundamental Analysis

USA - NASDAQ:MURA - IE000LK2BOB4 - Common Stock

2.09 USD
-0.01 (-0.48%)
Last: 10/31/2025, 8:01:55 PM
Fundamental Rating

2

Taking everything into account, MURA scores 2 out of 10 in our fundamental rating. MURA was compared to 534 industry peers in the Biotechnology industry. While MURA seems to be doing ok healthwise, there are quite some concerns on its profitability. MURA does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year MURA has reported negative net income.
In the past year MURA has reported a negative cash flow from operations.
MURA Yearly Net Income VS EBIT VS OCF VS FCFMURA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 -50M -100M -150M -200M

1.2 Ratios

MURA's Return On Assets of -168.07% is on the low side compared to the rest of the industry. MURA is outperformed by 87.64% of its industry peers.
Looking at the Return On Equity, with a value of -250.33%, MURA is doing worse than 69.48% of the companies in the same industry.
Industry RankSector Rank
ROA -168.07%
ROE -250.33%
ROIC N/A
ROA(3y)-235.67%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MURA Yearly ROA, ROE, ROICMURA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 0 -2K -4K -6K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for MURA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MURA Yearly Profit, Operating, Gross MarginsMURA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024

More info and screens

5

2. Health

2.1 Basic Checks

MURA has more shares outstanding than it did 1 year ago.
There is no outstanding debt for MURA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
MURA Yearly Shares OutstandingMURA Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 5M 10M 15M
MURA Yearly Total Debt VS Total AssetsMURA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

MURA has an Altman-Z score of -7.48. This is a bad value and indicates that MURA is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of MURA (-7.48) is worse than 68.16% of its industry peers.
There is no outstanding debt for MURA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -7.48
ROIC/WACCN/A
WACCN/A
MURA Yearly LT Debt VS Equity VS FCFMURA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

MURA has a Current Ratio of 2.87. This indicates that MURA is financially healthy and has no problem in meeting its short term obligations.
MURA has a Current ratio of 2.87. This is in the lower half of the industry: MURA underperforms 65.54% of its industry peers.
MURA has a Quick Ratio of 2.87. This indicates that MURA is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 2.87, MURA is not doing good in the industry: 63.48% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 2.87
Quick Ratio 2.87
MURA Yearly Current Assets VS Current LiabilitesMURA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

1

3. Growth

3.1 Past

MURA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 17.06%, which is quite good.
EPS 1Y (TTM)17.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5.38%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 11.94% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y23.84%
EPS Next 2Y39.55%
EPS Next 3Y25.65%
EPS Next 5Y11.94%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MURA Yearly Revenue VS EstimatesMURA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 100M 200M 300M
MURA Yearly EPS VS EstimatesMURA Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 -4 -6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MURA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MURA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MURA Price Earnings VS Forward Price EarningsMURA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MURA Per share dataMURA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4 -6

4.3 Compensation for Growth

MURA's earnings are expected to grow with 25.65% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.55%
EPS Next 3Y25.65%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MURA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MURAL ONCOLOGY PLC

NASDAQ:MURA (10/31/2025, 8:01:55 PM)

2.09

-0.01 (-0.48%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-04 2025-08-04/bmo
Earnings (Next)11-12 2025-11-12
Inst Owners54.49%
Inst Owner ChangeN/A
Ins Owners1.81%
Ins Owner Change-0.74%
Market Cap36.20M
Revenue(TTM)N/A
Net Income(TTM)-147152000
Analysts45.71
Price Target6.12 (192.82%)
Short Float %2.96%
Short Ratio1.57
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-10.61%
Min EPS beat(2)-28.77%
Max EPS beat(2)7.55%
EPS beat(4)2
Avg EPS beat(4)-3.94%
Min EPS beat(4)-28.77%
Max EPS beat(4)7.55%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)43.45%
EPS NY rev (1m)12.32%
EPS NY rev (3m)-5.86%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.62
P/tB 0.62
EV/EBITDA N/A
EPS(TTM)-7.57
EYN/A
EPS(NY)-0.4
Fwd EYN/A
FCF(TTM)-7.51
FCFYN/A
OCF(TTM)-7.51
OCFYN/A
SpS0
BVpS3.39
TBVpS3.39
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -168.07%
ROE -250.33%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-235.67%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1.38%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.87
Quick Ratio 2.87
Altman-Z -7.48
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)167.92%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)17.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5.38%
EPS Next Y23.84%
EPS Next 2Y39.55%
EPS Next 3Y25.65%
EPS Next 5Y11.94%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y21.63%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year27.74%
EBIT Next 3Y25.8%
EBIT Next 5Y8.57%
FCF growth 1Y27.82%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y26.23%
OCF growth 3YN/A
OCF growth 5YN/A

MURAL ONCOLOGY PLC / MURA FAQ

What is the fundamental rating for MURA stock?

ChartMill assigns a fundamental rating of 2 / 10 to MURA.


What is the valuation status for MURA stock?

ChartMill assigns a valuation rating of 1 / 10 to MURAL ONCOLOGY PLC (MURA). This can be considered as Overvalued.


Can you provide the profitability details for MURAL ONCOLOGY PLC?

MURAL ONCOLOGY PLC (MURA) has a profitability rating of 0 / 10.


Can you provide the financial health for MURA stock?

The financial health rating of MURAL ONCOLOGY PLC (MURA) is 5 / 10.